Lynchburg Journal of Medical Science
Family Practice (Primary Care)
Dr. Mary Walton
The treatment of opioid use disorder in correctional medicine is a relatively novel concept that has become increasingly adopted over the last several years across the United States. Daily sublingual buprenorphine has been widely accepted as a first-line medication; however, the long-acting injectable formulation of buprenorphine may be a more effective option for treating incarcerated patients. The long-acting formulation of buprenorphine is superior to daily sublingual buprenorphine in terms of patient compliance and treatment retention post-release, less frequent dosing, decreased diversion risk in the prison, and reduced patient care episodes as well as staff involvement following the initiation of care.
Goudreau S. Treatment of Opioid Use Disorder in the Incarcerated Population. Lynchburg Journal of Medical Science. 2023; 5(1).
Available when accessing via a campus IP address or logged in with a University of Lynchburg email address.
Off-campus users can also use 'Off-campus Download' button above for access.